跳转至内容
Merck
CN

11702

杆菌肽

from Bacillus licheniformis, ≥65 IU/mg

别名:

Altracin, Bacitracin A

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C66H103N17O16S
化学文摘社编号:
分子量:
1422.69
NACRES:
NA.85
PubChem Substance ID:
UNSPSC Code:
51282002
EC Number:
215-786-2
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35?,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48?,52?,53-,54-/m0/s1

InChI key

CLKOFPXJLQSYAH-RNHDWVCBSA-N

SMILES string

[H]N1[C@@H](Cc2cnc[nH]2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)C3CSC(=N3)C(N)C(C)CC)[C@@H](C)CC)C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](Cc4ccccc4)C1=O

biological source

Bacillus licheniformis

form

powder

specific activity

≥65 IU/mg

color

white to pale buff

antibiotic activity spectrum

Gram-positive bacteria

mode of action

cell wall synthesis | interferes

storage temp.

2-8°C

Quality Level

正在寻找类似产品? 访问 产品对比指南

General description

Chemical structure: peptide

Application

Bacitracin is used to study disruption of bacterial cell wall synthesis at the level of peptidoglycan biosynthesis and isoprenyl metabolism. It is also used to study the biosynthesis of sterols and squalene.
Bacitracin has been used:
  • as a protease inhibitor
  • as a control antibiotic
  • for the calibration in size exclusion chromatography

Biochem/physiol Actions

Peptide antibiotic.
Antimicrobial spectrum: Gram-positive bacteria.
Mode of Action: Inhibits bacterial cell wall synthesis by inhibiting dephosphorylation of lipid pyrophosphate.
Bacitracin has been shown to decrease vancomycin-resistant Enterococcus faecium population in intestine.

Packaging

5G, 25 G

Other Notes

Keep container tightly closed in a dry and well-ventilated place. Moisture sensitive. Keep in a dry place.

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Oral Bacitracin: A Consideration for Suppression of Intestinal Vancomycin-Resistant Enterococci (VRE) and for VRE Bacteremia From an Apparent Gastrointestinal Tract Source.
Truc T Tran et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 60(11), 1726-1728 (2015-02-24)
Ashwantha Kumar Enjapoori et al.
Genome biology and evolution, 6(10), 2754-2773 (2014-09-24)
Monotremes (platypus and echidna) are the descendants of the oldest ancestor of all extant mammals distinguished from other mammals by mode of reproduction. Monotremes lay eggs following a short gestation period and after an even briefer incubation period, altricial hatchlings
Anthony W Kingston et al.
Molecular microbiology, 93(1), 37-49 (2014-05-09)
Heptaprenyl diphosphate (C35 -PP) is an isoprenoid intermediate in the synthesis of both menaquinone and the sesquarterpenoids. We demonstrate that inactivation of ytpB, encoding a C35 -PP utilizing enzyme required for sesquarterpenoid synthesis, leads to an increased sensitivity to bacitracin
Hiromasa Tsuda et al.
Antimicrobial agents and chemotherapy, 46(12), 3756-3764 (2002-11-19)
Streptococcus mutans is resistant to bacitracin, which is a peptide antibiotic produced by certain species of Bacillus. The purpose of this study was to clarify the bacitracin resistance mechanism of S. mutans. We cloned and sequenced two S. mutans loci
Kazuhiko Nakano et al.
Nature communications, 2, 485-485 (2011-09-29)
Although several risk factors for stroke have been identified, one-third remain unexplained. Here we show that infection with Streptococcus mutans expressing collagen-binding protein (CBP) is a potential risk factor for haemorrhagic stroke. Infection with serotype k S. mutans, but not

商品

β-lactam antibacterials inhibit transpeptidase enzymes, preventing peptidoglycan assembly in both Gram-positive and Gram-negative bacteria.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持